Answers are grounded in this paper and cite their sources.
Background Childhood-onset Still's disease is a severe autoinflammatory disease characterized by systemic inflammation and risk of macrophage activation syndrome (MAS). Early cytokine-targeted therapy, particularly interleukin-1 (IL-1) inhibition, has been proposed to modify disease trajectory and improve long-term outcomes. Methods We conducted a single-center retrospective cohort study of children with childhood-onset Still's disease followed between January 2018 and December 2025. Clinical inactive disease (CID) was defined according to Wallace criteria. Treatment patterns, biologic switching, MAS occurrence, biomarker normalization, and treatment-free remission were evaluated. Results Eighteen patients were included (50% female), with a median age at symptom onset of 6.5 years. First-line biologic therapy consisted predominantly of IL-1 inhibition [94.4% ( n = 17)]. Biologic switching occurred in 77.8% ( n = 14) of patients, primarily due to treatment burden related to daily injections. CID was achieved in 11.1% ( n = 2) of patients at 1 month, 66.7% ( n = 12) at 3 months, and 94.4% ( n = 17) at 6 months. MAS developed early in 44.4% ( n = 8) of patients, with no recurrent MAS episodes during follow-up. Among MAS patients, concomitant therapies included intravenous pulse methylprednisolone in all, IVIG in 62.5% ( n = 5), plasmapheresis in 37.5% ( n = 3), and cyclosporine in 62.5% ( n = 5). At last follow-up, 66.7% ( n = 12) of patients achieved treatment-free remission. The median duration of biologic therapy prior to discontinuation was 14.5 months (IQR: 12.0–18.0). A transient discrepancy between physician and patient/parent global assessments (“perception lag”) was observed during early treatment. Conclusion Early IL-1-targeted therapy was associated with rapid disease control, effective corticosteroid sparing, and high rates of treatment-free remission in childhood-onset Still's disease. These findings support early cytokine inhibition as a cornerstone of treat-to-target strategies and suggest a potential disease-modifying effect in Still's disease.
No takes yet. Share an insight, caveat, or question.
Yücel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: